Quintrio
Home

PHARMACEUTICAL PREPARATIONS

GT Biopharma Inc. Common Stock

GTBP

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Last trade $3.30
Day change -$0.24 (-6.79%)
Day range $3.30 – $4.30
Volume 61,834
Market cap $6M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.39M
Price / earnings
—
Price / book
1.79×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.09×

Profitability

Earnings per share
-$18.16
Return on assets
-566.02%
Return on equity
-917.93%
Dividend yield
3.59%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.61×
Quick ratio
2.61×
Cash ratio
2.24×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.43M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GTBP, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.46M$2.44M$4.22M$2.75M$1.15M$833K$1.83M$2.3M
Research and development$1.06M$413K$1.38M$634K$363K$1.1M$1.93M$1.31M
Total operating expenses$4.51M$2.85M$5.6M$3.38M$1.51M$1.93M$3.76M$3.6M
Operating income-$4.51M-$2.85M-$5.6M-$3.38M-$1.51M-$1.93M-$3.76M-$3.6M
Interest expense-$64K-$63K-$127K$0$0$0$0$0
Income before taxes-$4.52M-$2.83M-$23.03M$8.3M-$30.17M-$776K-$3.78M-$3.41M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.52M-$2.83M-$23.03M$8.3M-$30.17M-$776K-$3.78M-$3.41M
Net income attributable to common shareholders-$4.59M-$3.37M-$28.9M$4.1M-$30.25M-$776K-$3.78M-$3.41M
EBITDA-$4.51M-$2.85M-$5.6M-$3.38M-$1.51M-$1.93M-$3.76M-$3.6M
Basic earnings per share-$3.00-$2.75-$62.44$26.00-$273.00-$8.25-$41.71-$38.25
Diluted earnings per share-$3.00-$2.75-$62.44$26.00-$273.00-$8.25-$41.71-$38.25

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.

GlobeNewswire Inc.

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.

GlobeNewswire Inc.

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis

The market is shifting focus towards technologies that can detect previously invisible threats across healthcare, resource exploration, and diagnostics, with several companies developing innovative solutions for cardiac care, diabetes treatment, cancer therapy, and mineral exploration.

GlobeNewswire Inc.

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 8, 20261-for-25reverse split
Feb 5, 20241-for-30reverse split
Feb 11, 20211-for-17reverse split